Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (131-140 of 192) with videos related to

Pageof 20
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 1, 2026
Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinomaGael S Roth, Jérôme Cros, Cindy Neuzillet, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II TrialLouis Gros, Mohamed Bouattour, Clément Dumont, et al.
Cancers|November 13, 2021
Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric ExperienceCaroline Touloupas, Matthieu Faron, Julien Hadoux, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodologyMomar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
Journal of Neuroradiology = Journal De Neuroradiologie|July 13, 2023
Effects of weather conditions on endovascular treatment case volume for patients with ischemic strokeDavid Malka, Kevin Janot, Marco Pasi, et al.
Cancers|November 13, 2021
Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer PatientsJuliette Palle, Laure Hirsch, Alexandra Lapeyre-Prost, et al.
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effectsSimon Pernot, Cecile Badoual, Magali Terme, et al.
Pageof 20

Showing results (131-140 of 192) with videos related to

Sort By:
Pageof 20
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 1, 2026
Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinomaGael S Roth, Jérôme Cros, Cindy Neuzillet, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II TrialLouis Gros, Mohamed Bouattour, Clément Dumont, et al.
Cancers|November 13, 2021
Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric ExperienceCaroline Touloupas, Matthieu Faron, Julien Hadoux, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodologyMomar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
Journal of Neuroradiology = Journal De Neuroradiologie|July 13, 2023
Effects of weather conditions on endovascular treatment case volume for patients with ischemic strokeDavid Malka, Kevin Janot, Marco Pasi, et al.
Cancers|November 13, 2021
Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer PatientsJuliette Palle, Laure Hirsch, Alexandra Lapeyre-Prost, et al.
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effectsSimon Pernot, Cecile Badoual, Magali Terme, et al.
Pageof 20